Outcomes of COVID‐19 in multiple myeloma patients treated with daratumumab

Retrospective review of outcomes of Multiple Myeloma (MM) patients with COVID-19 infection (two-center study)

(2023) Hamid Ehsan et al.   Clinical Lymphoma Myeloma & Leukemia

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

(2023) Evangelos Terpos et al.   LEUKEMIA

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis

(2022) Ainsley Ryan Yan Bin Lee et al.   BMJ-British Medical Journal

Outcome of infection with omicron SARS‐CoV ‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

(2022) Ola Blennow et al.   AMERICAN JOURNAL OF HEMATOLOGY

Risk factors for severe infection and mortality In patients with COVID ‐19 in patients with multiple myeloma and AL amyloidosis

(2022) Matthew Ho et al.   AMERICAN JOURNAL OF HEMATOLOGY

Cumulative Incidence and Relative Risk of Infection in Multiple Myeloma Patients Treated with anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-Analysis

(2022) Stephanos Vassilopoulos et al.   Open Forum Infectious Diseases

Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China

(2022) Weiping Liu et al.   BONE MARROW TRANSPLANTATION

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience

(2021) Marta Krejci et al.   ANNALS OF HEMATOLOGY

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

(2021) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

(2021) Soledad Henriquez et al.   BLOOD

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

(2021) Heinz Ludwig et al.   Lancet Haematology

Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China

(2020) Fei Yu et al.   MICROBES AND INFECTION

Clinical Characteristics of Coronavirus Disease 2019 in China

(2020) Wei-jie Guan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy.

(2020) Gordon Cook et al.   BRITISH JOURNAL OF HAEMATOLOGY

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

(2020) Evangelos Terpos et al.   LEUKEMIA

COVID-19 in Immunocompromised Hosts: What We Know So Far

(2020) Monica Fung et al.   CLINICAL INFECTIOUS DISEASES

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy

(2020) Danai Dima et al.   Cancer Management and Research

Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors

(2020) Smith Giri et al.   JAMA Oncology

Racial and Ethnic Disparities in COVID-19–Related Infections, Hospitalizations, and Deaths

(2020) Katherine Mackey et al.   ANNALS OF INTERNAL MEDICINE

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

(2020) Ajai Chari et al.   BLOOD

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma

(2019) Hareth Nahi et al.   PLoS One

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

(2019) Thierry Facon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

(2019) Philippe Moreau et al.   LANCET

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

(2019) Maria-Victoria Mateos et al.   Clinical Lymphoma Myeloma & Leukemia

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

(2019) Maria-Victoria Mateos et al.   LANCET

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach

(2015) Evren Alici et al.   BRITISH JOURNAL OF HAEMATOLOGY

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

(2014) C. Blimark et al.   HAEMATOLOGICA

The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report

(2010) Andrew S. Levey et al.   KIDNEY INTERNATIONAL